CRANBURY, N.J., Nov. 11 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD), today announced President and CEO, John F. Crowley, will make a presentation at the 5th Annual Lazard Capital Markets Healthcare Conference in New York on Tuesday, November 18, 2008, at 5:10 p.m. EST.
A webcast and audio archive of the presentation will be available at the Company's Web site at http://www.amicustherapeutics.com. Participants should allow approximately five to ten minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast. A replay of the webcast will also be available on the Company's Web site for 30 days until December 18, 2008.
About Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease.
Amicus' press releases are available at http://www.amicustherapeutics.com
|SOURCE Amicus Therapeutics|
Copyright©2008 PR Newswire.
All rights reserved